Outcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell Chondrosarcoma.

BACKGROUND Chondrosarcoma is a heterogeneous group of primary bone sarcoma with an excellent overall survival after local therapy. However, the small percentage of patients who have no surgical treatment options have a very poor prognosis. We retrospectively collected data from these patients in four sarcoma centers and compared the progression-free survival (PFS) for the different treatment regimens used for the four chondrosarcoma subtypes. MATERIALS AND METHODS Patients diagnosed with unresectable chondrosarcoma in all four major sarcoma centers were included, and data on first-line systemic therapy were retrospectively collected for analysis. RESULTS A total of 112 patients were enrolled in this retrospective analysis: 50 conventional, 25 mesenchymal, 34 dedifferentiated, and 3 clear cell chondrosarcoma patients. In conventional chondrosarcoma patients, the longest mean PFS (6.7 months) was found in the group treated with antihormonal therapy. Patients diagnosed with mesenchymal chondrosarcoma were all treated with multidrug chemotherapy, and the mean PFS was 6.7 months. Doxorubicin monotherapy seems to have an unexplained better PFS than doxorubicin-based combination therapy in patients with dedifferentiated chondrosarcoma (5.5 vs. 2.8 months, respectively; p = .275). CONCLUSION Prospective studies need to be conducted based on preclinical work to develop a uniform regimen to treat advanced chondrosarcoma patients according to the diagnosed subtype and improve survival. IMPLICATIONS FOR PRACTICE Currently, there are no uniform treatment lines for advanced chondrosarcoma patients, which results in a very diverse group of treatment regimens being used. In this study, the data of 112 patients was collected. It was concluded that some treatment regimens seem to have a better progression-free survival compared with others, and that these results also differ between the chondrosarcoma subtypes. Prospective studies need to be conducted based on preclinical work to develop a uniform regimen to treat advanced chondrosarcoma patients according to the diagnosed histological subtype to improve their survival.

[1]  Wei Hu,et al.  Insulin-Like Growth Factor 1 (IGF1) Pathway Member Polymorphisms Are Associated with Risk and Prognosis of Chondrosarcoma , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[2]  S. Costantini,et al.  Inhibiting Monocyte Recruitment to Prevent the Pro-Tumoral Activity of Tumor-Associated Macrophages in Chondrosarcoma , 2020, Cells.

[3]  S. Choe,et al.  Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Nielsen,et al.  Prognostic Factors in Dedifferentiated Chondrosarcoma: A Retrospective Analysis of a Large Series Treated at a Single Institution , 2019, Sarcoma.

[5]  W. Mendenhall,et al.  Proton therapy for skull-base chondrosarcoma, a single-institution outcomes study , 2019, Journal of Neuro-Oncology.

[6]  A. Cleton-Jansen,et al.  IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas , 2017, Clinical Sarcoma Research.

[7]  H. Tawbi,et al.  Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor , 2017, Cancer.

[8]  K. Yen,et al.  IDH mutations in cancer and progress toward development of targeted therapeutics. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  A. Rosenberg,et al.  Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells , 2015, PloS one.

[10]  K. Woltjen,et al.  Mutant IDH1 Dysregulates the Differentiation of Mesenchymal Stem Cells in Association with Gene-Specific Histone Modifications to Cartilage- and Bone-Related Genes , 2015, PloS one.

[11]  A. Cleton-Jansen,et al.  The oncometabolite D-2-hydroxyglutarate induced by mutant IDH1 or -2 blocks osteoblast differentiation in vitro and in vivo , 2015, Oncotarget.

[12]  A. Cleton-Jansen,et al.  Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines , 2015, Oncotarget.

[13]  D. Biau,et al.  Mesenchymal chondrosarcoma: prognostic factors and outcome in 113 patients. A European Musculoskeletal Oncology Society study. , 2015, European journal of cancer.

[14]  S. Ferrari,et al.  Outcome of advanced, unresectable conventional central chondrosarcoma , 2014, Cancer.

[15]  B. Alman,et al.  Hedgehog Pathway Inhibition in Chondrosarcoma Using the Smoothened Inhibitor IPI-926 Directly Inhibits Sarcoma Cell Growth , 2014, Molecular Cancer Therapeutics.

[16]  F. Bertucci,et al.  Advanced chondrosarcomas: role of chemotherapy and survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  B. van de Water,et al.  Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells , 2013, British Journal of Cancer.

[18]  A. Mavrogenis,et al.  Survival analysis of patients with chondrosarcomas of the pelvis , 2013, Journal of surgical oncology.

[19]  C. Fletcher,et al.  WHO classification of tumours of soft tissue and bone , 2013 .

[20]  N. Socci,et al.  Identification of a novel, recurrent HEY1‐NCOA2 fusion in mesenchymal chondrosarcoma based on a genome‐wide screen of exon‐level expression data , 2012, Genes, chromosomes & cancer.

[21]  R. Sciot,et al.  Somatic mosaic IDH1 or IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome , 2011, Nature Genetics.

[22]  A. Cleton-Jansen,et al.  Expression of aromatase and estrogen receptor alpha in chondrosarcoma, but no beneficial effect of inhibiting estrogen signaling both in vitro and in vivo , 2011, Clinical Sarcoma Research.

[23]  A. Grigoriadis,et al.  IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours , 2011, The Journal of pathology.

[24]  T. van Wezel,et al.  Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. , 2009, Cancer research.

[25]  A. Cleton-Jansen,et al.  Aberrant heparan sulfate proteoglycan localization, despite normal exostosin, in central chondrosarcoma. , 2009, The American journal of pathology.

[26]  S. Bielack,et al.  Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults , 2008, Cancer.

[27]  J. Brooks,et al.  Immunohistochemical Expression of Estrogen Receptors in Chondrosarcomas and Enchondromas , 2008, International journal of surgical pathology.

[28]  D. Biau,et al.  Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. , 2007, European journal of cancer.

[29]  S. Ferrari,et al.  Mesenchymal Chondrosarcoma. An Analysis of Patients Treated at a Single Institution , 2007, Tumori.

[30]  F. Bertoni,et al.  Dedifferentiated central chondrosarcoma , 2006, Cancer.

[31]  B. Alman,et al.  Constitutive hedgehog signaling in chondrosarcoma up-regulates tumor cell proliferation. , 2006, The American journal of pathology.

[32]  A. Cleton-Jansen,et al.  Estrogen Signaling Is Active in Cartilaginous Tumors: Implications for Antiestrogen Therapy as Treatment Option of Metastasized or Irresectable Chondrosarcoma , 2005, Clinical Cancer Research.

[33]  R. Grimer,et al.  Experience in the treatment of dedifferentiated chondrosarcoma. , 2000, The Journal of bone and joint surgery. British volume.

[34]  G. Rosen,et al.  Mesenchymal chondrosarcoma a clinicopathologic analysis of 35 patients with emphasis on treatment , 1983, Cancer.